IOVA CLASS NOTICE: Iovance Biotherapeutics, Inc. Investors may have been Affected by Fraud – Contact BFA Law before July 14 Court Deadline (NASDAQ:IOVA)

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, following disappointing financial results and issues with its melanoma treatment, Amtagvi [1][2][5]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and high patient drop-off rates due to ineffective patient identification and selection [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates [5]. - Following the announcement of these results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].